TheStreet lowered shares of Mylan (NASDAQ:MYL) from a b- rating to a c+ rating in a report published on Friday morning.

Several other research firms have also recently weighed in on MYL. Zacks Investment Research cut shares of Mylan from a hold rating to a sell rating in a research report on Tuesday, January 9th. BidaskClub upgraded shares of Mylan from a hold rating to a buy rating in a research report on Friday, October 27th. Leerink Swann initiated coverage on shares of Mylan in a research report on Tuesday, January 2nd. They issued a market perform rating and a $44.00 price objective on the stock. Mizuho restated a buy rating and issued a $37.00 price objective on shares of Mylan in a research report on Tuesday, October 24th. Finally, Cantor Fitzgerald set a $34.00 price objective on shares of Mylan and gave the stock a hold rating in a research report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. Mylan presently has a consensus rating of Buy and an average price target of $44.65.

Mylan (MYL) opened at $40.60 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The firm has a market cap of $21,071.22, a P/E ratio of 25.22, a P/E/G ratio of 1.06 and a beta of 1.35. Mylan has a 52-week low of $29.39 and a 52-week high of $47.82.

In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.69% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of MYL. Pzena Investment Management LLC grew its holdings in shares of Mylan by 84.1% in the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after purchasing an additional 10,381,697 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Mylan in the fourth quarter worth approximately $137,023,000. Schroder Investment Management Group grew its holdings in shares of Mylan by 74.7% in the third quarter. Schroder Investment Management Group now owns 3,026,172 shares of the company’s stock worth $93,388,000 after purchasing an additional 1,294,400 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Mylan by 30.3% in the fourth quarter. Bank of New York Mellon Corp now owns 5,334,789 shares of the company’s stock worth $225,715,000 after purchasing an additional 1,239,089 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Mylan by 72.9% in the fourth quarter. Wells Fargo & Company MN now owns 2,560,305 shares of the company’s stock worth $108,326,000 after purchasing an additional 1,079,696 shares during the last quarter. Hedge funds and other institutional investors own 75.56% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Mylan (MYL) Rating Lowered to C+ at TheStreet” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/02/13/mylan-myl-rating-lowered-to-c-at-thestreet.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.